see beelow

Study phase II open label study using triheptanoin in patients with a deficiency of glmucose transporter type 1 (GLUT-1) - GLUTHEP

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-003920-32-FR

Enrollment

Registered

2019-11-12

Start date

2013-11-26

Completion date

Unknown

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N/A MedDRA version: 20.0 Level: HLGT Classification code 10039911 Term: Seizures (incl subtypes) System Organ Class: 10029205 - Nervous system disorders

Interventions

Product Name: Triheptanoin Product Code: UX007 Pharmaceutical Form: Oral solution INN or Proposed INN: Not available CAS Number: 620-67-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: N/A Are the trial subjects under 18? yes Number of subjects for this age range: 10 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 9 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 1

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

Measure	Time frame
Main Objective: N/A;Secondary Objective: N/A;Primary end point(s): N/A;Timepoint(s) of evaluation of this end point: N/A	—

Secondary

Measure	Time frame
Secondary end point(s): N/A	—

Countries

France

Contacts

Public ContactSonia GUEGUEN

INSERM

rqrc.siege@inserm.fr33144236047

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026